Guggenheim initiates First Tracks Biotherapeutics Buy, $100 target
Guggenheim initiated coverage on First Tracks’s stock with a Buy rating and a $100.00 price target, implying 159.9% upside from the Sep 15 close of $38.47.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.